Cocrystal Pharma, Inc. (COCP)

Compare

1.4300

+0.0100

+(0.70%)

At close: 4:00:01 PM EDT

1.3635

-0.07

(-4.65%)

After hours: 6:43:00 PM EDT

COCP: Norovirus Challenge Study Planned for 2025…

By David Bautz, PhD NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Business Update Update on CDI-988 On January 8, 2025, Cocrystal Pharma, Inc. (NASDAQ:COCP) announced results from the Phase 1 trial of CDI-988 for the prophylaxis and treatment of norovirus, coronavirus, and other viral infections. The results showed the drug had a favorable safety and tolerability profile for dosing up to 800 mg

Zacks Small Cap Research yesterday

COCP
+0.70%
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

BOTHELL, Wash., March 31, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the 12 months ended December 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. “Our novel, potent antiviral compounds for norovirus, influenza and coronavirus address critical gaps in global health where effective treatments or vaccines are currently lacking,” said Sam Lee, Ph.D., Preside

GlobeNewswire 2 days ago

COCP
+0.70%
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3DIWqav The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download

GlobeNewswire 19 days ago

PDSB

TELIF

BPTSY
Life Sciences Investor Forum Agenda Announced for March 13th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4hnure6 It is recommended that inve

GlobeNewswire 21 days ago

NGENF

BPTSY

HMTXF
Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

BOTHELL, Wash., March 06, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in a fireside chat at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025 at 11:30 a.m. Eastern time (8:30 a.m. Pacific time). The fireside chat will be hosted by Zacks Small Cap Research Senior Analyst David Bautz, PhD. Pre-register for Cocrystal’s virtual presentation is available on the Cocrystal website here. Investors will have the op

GlobeNewswire 27 days ago

COCP
+0.70%
Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch

As the U.S. stock market navigates through a landscape marked by tariff discussions and Federal Reserve policy updates, investors are keeping a close eye on how these factors influence broader indices like the Dow Jones, S&P 500, and Nasdaq. Penny stocks may be a throwback term, but the opportunities they represent are far from old news. Typically referring to smaller or newer companies, these stocks present an underappreciated chance for growth at lower price points. When combined with...

Simply Wall St. last month

KNDI

COCP
+0.70%
TOUR
COCP: Phase 2a Trial of CC-42344 Extended…

By David Bautz, PhD NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Business Update Phase 2a Trial of CC-42344 Extended On December 31, 2024, Cocrystal Pharma, Inc. (NASDAQ:COCP) announced that the Phase 2a clinical trial of its oral PB2 inhibitor, CC-42344, will be extended due to unexpectedly low infection rates among trial participants that were challenged with a H3N2 influenza strain. The

Zacks Small Cap Research 2 months ago

COCP
+0.70%
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study in 2025 in norovirus-infected subjects BOTHELL, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces favorable safety and tolerability results at dosing up to 800 mg per day for 10 consecutive days from the multiple-ascending dose (MAD) portion of the ongoing Phase 1 study with its oral protease inhibitor CDI-98

GlobeNewswire 2 months ago

COCP
+0.70%
Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial

The company reported the enrolment of the trial’s first subject in December 2023.

Clinical Trials Arena 2 months ago

COCP
+0.70%
Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement

Antiviral medicines are developed using a unique structure-based drug discovery platform.

GuruFocus.com 2 months ago

COCP
+0.70%
Top Midday Decliners

Sangamo Therapeutics (SGMO) shares plunged 55%, a day after the company said its partner, Pfizer (PF

PREMIUM
MT Newswires 2 months ago

SGMO

COCP
+0.70%
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended due to low influenza infection among challenged participants; virology results are uninterpretable BOTHELL, Wash., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces plans to extend enrollment in the Phase 2a human challenge study with its investigational, broad-spectrum, oral inf

GlobeNewswire 2 months ago

COCP
+0.70%
US Penny Stocks To Watch In December 2024

As the Federal Reserve's meeting on interest rates takes center stage, the U.S. markets are experiencing a mix of anticipation and caution, with indices like the Dow Jones facing consecutive declines while others hit record highs. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired...

Simply Wall St. 3 months ago

COCP
+0.70%
MITQ
COCP: Multiple Upcoming Catalysts…

By David Bautz, PhD NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Business Update Multiple Upcoming Catalysts Cocrystal Pharma, Inc. (NASDAQ:COCP) has multiple upcoming catalysts over the next few months as it develops CC-42344 as a treatment for influenza and CDI-988 as a treatment for both coronavirus and norovirus infections. Before the end of 2024, we expect Cocrystal to report topline

Zacks Small Cap Research 4 months ago

COCP
+0.70%
November 2024 US Exchange Standouts: Promising Penny Stocks

As the U.S. stock market navigates a "sometimes-bumpy path" toward its inflation target, as noted by Fed Chair Jerome Powell, investors are closely watching for opportunities amidst fluctuating indices. Penny stocks, though an older term, remain relevant by highlighting smaller or less-established companies that can offer substantial value. By focusing on those with strong financials and clear growth potential, investors may find promising opportunities within this often-overlooked segment of...

Simply Wall St. 4 months ago

PHX

COCP
+0.70%
ZEPP
Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

BOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. “The coming months are critically important to Cocrystal as we expect to report topline results from two ongoing clinical studies with our best-in-class antiviral candidates in major medical indicat

GlobeNewswire 4 months ago

COCP
+0.70%
Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins

The Company’s antiviral candidate for seasonal and pandemic influenza shows in vitro activity against the avian influenza A PB2 protein, whereas current influenza vaccines offer no protection against pandemic avian influenza BOTHELL, Wash., Oct. 31, 2024 (GLOBE NEWSWIRE) -- As the fall seasonal influenza and COVID season gets underway in the Northern Hemisphere, Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) highlights the ability of the Company’s innovative structure-based

GlobeNewswire 4 months ago

COCP
+0.70%
Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 5 months ago

COCP
+0.70%
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts

BOTHELL, Wash., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988, its potent, broad-spectrum, oral pan-viral protease inhibitor. Topline study results are expected in late 2024 or early 2025. CDI-988 was specifically designed and developed using Cocrystal’s proprietary structure-based drug discovery platform technology and is

GlobeNewswire 6 months ago

COCP
+0.70%
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

BOTHELL, Wash., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.’s (Nasdaq: COCP) management announces its participation in the upcoming Virtual Investor Summit Microcap Forum in August and the H.C. Wainwright 26th Annual Global Investment Conference in September. “We look forward to showcasing key near-term clinical milestones at two upcoming investment conferences,” said James Martin, CFO and co-CEO of Cocrystal. “We expect to report topline results in 2024 from our influenza A Phase 2

GlobeNewswire 7 months ago

COCP
+0.70%

Performance Overview

Return	COCP	S&P 500 (^GSPC)
YTD	-29.21%	-3.58%
1-Year	-3.38%	+8.94%
3-Year	-77.52%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cocrystal Pharma, Inc. (COCP)

COCP: Norovirus Challenge Study Planned for 2025…

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for March 13th

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch

COCP: Phase 2a Trial of CC-42344 Extended…

Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial

Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement

Top Midday Decliners

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

US Penny Stocks To Watch In December 2024

COCP: Multiple Upcoming Catalysts…

November 2024 US Exchange Standouts: Promising Penny Stocks

Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Performance Overview